GlaxoSmithKline (GSK) today announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab,
An investigational IL-5 antagonist, in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) (Churg Strauss Syndrome).
Whoo Hoooo! Although I hope I never need it....fingers crossed. It's good to have as back up though.
Start a Community